Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $900.00 Price Target at Wells Fargo & Company

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lowered by analysts at Wells Fargo & Company from $1,050.00 to $900.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 22.68% from the stock’s current price.

REGN has been the topic of a number of other research reports. Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Citigroup assumed coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They set a “neutral” rating and a $895.00 price objective for the company. Royal Bank of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Finally, Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,037.33.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $733.59 on Friday. The firm’s 50-day moving average is $754.37 and its two-hundred day moving average is $965.13. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock has a market capitalization of $80.61 billion, a P/E ratio of 18.15, a P/E/G ratio of 2.19 and a beta of 0.10. Regeneron Pharmaceuticals has a 12-month low of $693.00 and a 12-month high of $1,211.20.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently bought and sold shares of REGN. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Fairfield Financial Advisors LTD acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $37,000. Ashton Thomas Private Wealth LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $39,000. Finally, Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $39,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.